184 related articles for article (PubMed ID: 19887800)
1. Variability in the prescription of cholinesterase inhibitors and memantine.
Villar-Fernández I; Bjerrum L; Feja C; Rabanaque MJ
Dement Geriatr Cogn Disord; 2009; 28(4):373-9. PubMed ID: 19887800
[TBL] [Abstract][Full Text] [Related]
2. [Use of specific drugs for Alzheimer's disease].
Villar Fernández I; Rabaneque Hernández MJ; Armesto Gómez J; García Arilla E; Izuel Rami M
Neurologia; 2007 Jun; 22(5):275-84. PubMed ID: 17508301
[TBL] [Abstract][Full Text] [Related]
3. Cholinesterase inhibitors and memantine have a role in the treatment of Alzheimer's disease.
Rabins PV; Lyketsos CG
Nat Clin Pract Neurol; 2006 Nov; 2(11):578-9. PubMed ID: 17057739
[No Abstract] [Full Text] [Related]
4. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
5. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
[TBL] [Abstract][Full Text] [Related]
6. Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populations.
Gilligan AM; Malone DC; Warholak TL; Armstrong EP
Am J Geriatr Pharmacother; 2012 Oct; 10(5):303-12. PubMed ID: 23063286
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
Bullock R
Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
[TBL] [Abstract][Full Text] [Related]
8. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
9. Consumption trends for specific drugs used to treat dementia in the region of Madrid (Spain) from 2002 to 2012.
de Hoyos-Alonso MC; Tapias-Merino E; Meseguer Barros CM; Sánchez-Martínez M; Otero A
Neurologia; 2015 Sep; 30(7):416-24. PubMed ID: 24704249
[TBL] [Abstract][Full Text] [Related]
10. [The action of memantine on the cognitive disorders of patients with dementia: reflections following two years' experience in Spain].
Robles-Bayón A
Rev Neurol; 2006 Mar 1-15; 42(5):288-96. PubMed ID: 16538592
[TBL] [Abstract][Full Text] [Related]
11. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors.
Jones RW
Int J Geriatr Psychiatry; 2010 Jun; 25(6):547-53. PubMed ID: 20049770
[TBL] [Abstract][Full Text] [Related]
12. [New options for the pharmacotherapy of Alzheimer disease after the approval of memantine? Re the article from DMW 8/2005].
Wellhöfer B
Dtsch Med Wochenschr; 2006 Feb; 131(6):284. PubMed ID: 16463237
[No Abstract] [Full Text] [Related]
13. Factors affecting usage patterns of memantine in Alzheimer disease.
Lerner AJ; McClendon MJ; Sami SA; Ogrocki PK; Adams KB; Smyth KA
Alzheimer Dis Assoc Disord; 2008; 22(2):137-43. PubMed ID: 18525285
[TBL] [Abstract][Full Text] [Related]
14. Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany.
Hoffmann F; van den Bussche H; Glaeske G; Kaduszkiewicz H
Int Clin Psychopharmacol; 2010 Jan; 25(1):29-36. PubMed ID: 19934763
[TBL] [Abstract][Full Text] [Related]
15. FDA approves groundbreaking Alzheimer's drug.
Provider; 2004 Feb; 30(2):24, 27. PubMed ID: 14964917
[No Abstract] [Full Text] [Related]
16. [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
Schölzel-Dorenbos CJ;
Tijdschr Gerontol Geriatr; 2005 Jul; 36(3):122-6. PubMed ID: 16078659
[TBL] [Abstract][Full Text] [Related]
17. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease.
Degerman Gunnarsson M; Kilander L; Basun H; Lannfelt L
Dement Geriatr Cogn Disord; 2007; 24(4):247-52. PubMed ID: 17700020
[TBL] [Abstract][Full Text] [Related]
18. New developments in the treatment of Alzheimer's disease.
J Clin Psychiatry; 2009 Feb; 70(2):281-90. PubMed ID: 19265644
[No Abstract] [Full Text] [Related]
19. [Efficacy of memantine in the treatment of Alzheimer's disease].
Molinuevo Guix JL; Lladó Plarrumaní A
Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
[TBL] [Abstract][Full Text] [Related]
20. Memantine for treatment of moderate to severe Alzheimer's disease.
Perras C
Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
